Quebec, Canada
OxyNov, founded in 2009 and headquartered in Canada, intends to transform oxygen therapy within healthcare settings. As leaders in the development of advanced respiratory care technologies, their innovation—the FreeO2—automatically adjusts oxygen flow based on the patient's real-time needs. This reduces risks associated with hyperoxia and hypoxemia, and provides constant monitoring of patient cardiopulmonary status.
The company operates at the intersection of Health Care, Medical Devices, and Pharmaceutical industries. Emphasizing safety, quality of life improvements, and cost-efficient patient care, OxyNov seeks to address the growing demands on hospital resources.
During their most recent funding event, a $500.00K investment round in May 2017, OxyNov secured backing from strategic partners including Desjardins-Innovatech and Health Technology Catalyst | CTS. Investors considering OxyNov will find a company focused on scalable innovation in patient care.
